The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 21, 2024
Filed:
Aug. 31, 2018
Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;
Sorbonne Universite, Paris, FR;
Universite DE Paris, Paris, FR;
Assistance Publique—hopitaux DE Paris, Paris, FR;
Francine Behar-Cohen, Paris, FR;
Raphael Cohen, Paris, FR;
Rinath Levy-Boukris, Paris, FR;
Min Zhao, Paris, FR;
INSERM (INSTITUT NATIONAL DE LASANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
SORBONNE UNIVERSITE, Paris, FR;
UNIVERSITE DE PARIS, Paris, FR;
ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris, FR;
Abstract
This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.